My watch list
my.bionity.com  
Login  

48 Current news of Actelion

rss
matching the following criteria

Actelion creates Vaxxilon together with the Max Planck Society

29-Jun-2015

Actelion Ltd announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines. The new company, Vaxxilon, aims to discover, develop, and commercialize synthetic carbohydrate vaccines. Vaxxilon has licensed exclusive rights to multiple ...

more

Actelion delivers strong half year operational and financial results

24-Jul-2014

Actelion Ltd announced its results for the first half of 2014: Product sales of CHF 993 million, up 17% at Constant Exchange Rates (CER),11% excluding US rebate reversals Core earnings of CHF 421 million, up 35% at CER, 21% excluding US rebate reversals Core EPS of CHF 3.25, an increase of 48% ...

more

Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study

17-Jun-2014

Actelion Ltd announced the top-line results of the pivotal Phase III GRIPHON study in 1,156 patients with pulmonary arterial hypertension (PAH) with selexipag, the first selective oral prostacyclin IP receptor agonist. Initial analysis shows that the event-driven outcome study has met its primary ...

more

Management change at Actelion

06-May-2014

Actelion Ltd announced that Roland Haefeli, Senior Vice President, Head of Investor Relations and Public Affairs (IR & PA) and member of the Extended Actelion Executive Committee (AEC) has decided to step down from his current role for personal reasons effective 05 May 2014. Roland Haefeli will ...

more

Actelion receives Health Canada approval of Opsumit

18-Nov-2013

Actelion Ltd announced that Health Canada has granted a Notice of Compliance (NOC) approving the orally available endothelin receptor antagonist OpsumitTM(macitentan) 10mg once daily for the treatment of pulmonary arterial hypertension (PAH). Opsumit (macitentan) is indicated in Canada, for the ...

more

Actelion is initiating Phase III clinical development of cadazolid in patients suffering from Clostridium difficile associated diarrhea

12-Sep-2013

Actelion announced that it will initiate a Phase III clinical development program to assess the efficacy and safety of cadazolid in patients with Clostridium difficile-associated diarrhea (CDAD).The Phase III program consists of two identical multi-center, randomized, double-blind studies ...

more

Actelion's novel antibiotic cadazolid to move into Phase III clinical development in patients suffering from Clostridium difficile associated diarrhea

04-Jan-2013

Actelion announced that it has decided to move forward with Phase III clinical development of cadazolid in patients suffering from Clostridium difficile associated diarrhea (CDAD). The decision is based on the results of a therapeutic exploratory Phase II dose-finding study randomizing 84 ...

more

Actelion's ponesimod successful in mid-stage trial in patients with plaque psoriasis

Ponesimod to proceed to Phase III clinical development in psoriasis

21-Dec-2012

Actelion announced that its selective S1P1 modulator, ponesimod, successfully met the primary endpoint - the proportion of patients with at least 75% improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI75) at week 16 - in a double blind, placebo-controlled study conducted ...

more

Actelion submits the registration dossier for macitentan to EMA

23-Nov-2012

Actelion announced that the submission of the Marketing Authorisation Application (MAA) for macitentan (Opsumit®) for the treatment of patients with pulmonary arterial hypertension to the EMA has been accepted. The EMA will now start the formal review process.The United States Food and Drug ...

more

Actelion submits a NDA for macitentan for the treatment of patients with pulmonary arterial hypertension

23-Oct-2012

Actelion announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for macitentan (Opsumit®) for the treatment of patients with pulmonary arterial hypertension.Macitentan, a novel oral dual endothelin receptor antagonist, was ...

more

Page 1 From 5
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE